^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Jeselhy (pimitespib) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Published date:
05/19/2021
Excerpt:
Eligible pts had histologically confirmed advanced GIST...were randomized 2:1 to receive either PIM 160 mg once daily on a 5-days-on/ 2-days-off schedule or PL....the results of PGx analysis suggested that PIM was also effective in pts with secondary KIT mutation detected from blood samples.
DOI:
10.1200/JCO.2021.39.15_suppl.11524
Source:
Title:
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Published date:
05/28/2020
Excerpt:
Median PFS was 2.8 months (mo) (95% CI: 1.6–2.9) for PIM vs. 1.4 mo (95% CI: 0.9–1.8) for PL. The hazard ratio (HR) for PFS was 0.51 (95% CI: 0.30–0.87) (p = 0.006, stratified log-rank test).....PIM was also effective in pts with secondary KIT mutation detected from blood samples….PIM significantly improved PFS with OS prolongation in pts with advanced GIST refractory to IM, SU, and REG, as a HSP90 inhibitor for the first time.
DOI:
10.1200/JCO.2021.39.15_suppl.11524
